Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Flocor (CytRx Corp).

¹ALZA Corp, PO Box 10950, Palo Alto, CA 94303-0802, USA. nishit.modi@alza.com

Idrugs : the Investigational Drugs Journal

|September 15, 2005

Summary

This summary is machine-generated.

Flocor, a purified poloxamer 188, shows promise for treating sickle cell crisis and acute respiratory distress syndrome. Its unique properties offer potential benefits for various vascular and inflammatory conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin.

Journal of clinical pharmacology·2008

Same author

Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.

International journal of impotence research·2005

Same author

Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers.

Xenobiotica; the fate of foreign compounds in biological systems·2005

Same author

Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.

Biopharmaceutics & drug disposition·2001

Same author

Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects.

Biopharmaceutics & drug disposition·2000

Same author

Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.

Journal of clinical pharmacology·2000

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Area of Science:

Biomedical Engineering
Pharmacology
Materials Science

Background:

CytRx is developing Flocor, a purified amphipathic copolymer (poloxamer 188), for critical medical conditions.
Flocor is being investigated for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury.

Purpose of the Study:

To evaluate Flocor as a therapeutic agent for acute sickle cell crisis.
To explore the potential of Flocor in treating ARDS/acute lung injury and acute ischemic vascular disorders.

Main Methods:

Flocor, a purified poloxamer 188, possesses specific physiochemical properties.
Clinical trials are underway, including Phase III for sickle cell crisis.

Main Results:

Related Experiment Videos

Flocor exhibits rheologic, cytoprotective, anti-adhesive, and antithrombotic effects.

It has demonstrated potential in managing conditions like stroke and myocardial infarction.

Conclusions:

Flocor is a promising therapeutic candidate with a favorable therapeutic index compared to its predecessor, RheothRx.
Regulatory submission (US NDA) is anticipated for late 1999 or 2000, leveraging existing data.